{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.02","upperLimit":"10.91","value":"4.86"},{"groupId":"OG001","lowerLimit":"2.86","upperLimit":"20.90","value":"12.02"},{"groupId":"OG002","lowerLimit":"2.04","upperLimit":"16.66","value":"5.06"},{"groupId":"OG003","lowerLimit":"1.74","upperLimit":"35.32","value":"11.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG000","title":"Diffuse Intrinsic Pontine Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG001","title":"Ependymoma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG002","title":"High-grade Glioma"},{"description":"Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.","id":"OG003","title":"Medulloblastoma"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat population includes all enrolled participants, regardless of whether they received any treatment or not","reportingStatus":"POSTED","timeFrame":"From the first dose of pomalidomide to the date of death due to any cause (Up to 71 months)","title":"Kaplan-Meier Estimate of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}